EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer

Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier

Cancer Immunology, Immunotherapy · 19.12.2025 · 75 (1)

DOI: 10.1007/s00262-025-04241-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.12.2025. Verfasst von Prashant Changoer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Thyroid Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Tyrosine kinase inhibitors, including lenvatinib approved for advanced non-medullary thyroid cancer (TC), affect the immune system. As tumor-related inflammation contributes to TC pathogenesis, this study assesses the immunomodulatory effects of lenvatinib, focusing on myeloid cells. METHODS: Peripheral blood was collected from 16 lenvatinib-treated and 15 untreated TC patients (cross-sectional cohort), and from eight patients before and after > 1 month of lenvatinib (longitudinal cohort). Immune profiling included cell subset counts, proteomic analyses, and ex vivo cytokine assays in peripheral blood mononuclear cells (PBMCs) and monocytes. Monocytes from healthy donors were used to evaluate metabolic activity, reactive oxygen species (ROS) production, and phagocytosis. Tumor-intrinsic effects of lenvatinib were studied by proteomics and immunophenotyping of the TPC-1 cell line. RESULTS: Lenvatinib increased lymphocytes and reduced neutrophils. In both cohorts, lenvatinib modulated the inflammatory proteome with elevated VEGFA, CCL11, MMP-10, and TRAIL. Monocytes exposed ex vivo to lenvatinib showed reduced production of IL-1β, IL-6, IL-8, and IL-10. In patients treated with lenvatinib, monocytes displayed increased IL-1Ra and TNF, while PBMCs exhibited enhanced IFN-γ production. Monocytes from healthy donors displayed reduced glycolysis and increased ROS after lenvatinib exposure. In TPC-1 cells, lenvatinib altered the secretome and upregulated MHC class I, PD-L1, and CD40. CONCLUSIONS: Lenvatinib treatment has broad immunomodulatory effects in patients with TC, including shifts in immune cell populations, changes in the proteome, and reprogramming of cytokine responses. Lenvatinib also impacts monocyte metabolism and tumor cell phenotype. These findings provide insight into the multifaceted immunological activities of lenvatinib and highlight opportunities for treatment strategies. TRIAL REGISTRATION: Not applicable, this is a noninterventional trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsThyroid NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleMaleMiddle AgedCross-Sectional StudiesCytokinesAdultAgedMonocytesLeukocytes, Mononuclear

Stichwörter der Autor:innen

Circulatory biomarkersImmunomodulationLenvatinibMacrophagesMonocytesNon-medullary thyroid carcinoma

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsCytokinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands. romana.netea-maier@radboudumc.nl.
  • Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. romana.netea-maier@radboudumc.nl.

Förderung

  • Eisai Europe

Zitieren

APA

Changoer, P., Peng, C., van Houten, P., van Emst, L., Walraven, J. E. W., Ottevanger, P. B., Jaeger, M., & Netea-Maier, R. T. (2025). Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer. Cancer Immunology, Immunotherapy, 75(1). https://doi.org/10.1007/s00262-025-04241-7

Vancouver

Changoer P, Peng C, van Houten P, van Emst L, Walraven JEW, Ottevanger PB, et al. Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer. Cancer Immunology, Immunotherapy. 2025;75(1). doi:10.1007/s00262-025-04241-7

BibTeX
@article{Changoer2025,
  author = {Changoer, Prashant and Peng, Chunying and van Houten, Pepijn and van Emst, Liesbeth and Walraven, Janneke E W and Ottevanger, Petronella B and Jaeger, Martin and Netea-Maier, Romana T},
  title = {Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {75},
  number = {1},
  doi = {10.1007/s00262-025-04241-7}
}
Kostenlos starten →